PT951292E - Métodos de tratamento de uma perturbação isquémica e de melhoria das consequências de acidente vascular cerebral. - Google Patents

Métodos de tratamento de uma perturbação isquémica e de melhoria das consequências de acidente vascular cerebral. Download PDF

Info

Publication number
PT951292E
PT951292E PT97944453T PT97944453T PT951292E PT 951292 E PT951292 E PT 951292E PT 97944453 T PT97944453 T PT 97944453T PT 97944453 T PT97944453 T PT 97944453T PT 951292 E PT951292 E PT 951292E
Authority
PT
Portugal
Prior art keywords
quot
stroke
selectin
cerebral
mice
Prior art date
Application number
PT97944453T
Other languages
English (en)
Portuguese (pt)
Inventor
David Stern
Ann Marie Schmidt
David J Pinsky
Eric A Rose
E Sander Connoly
Robert A Solomon
Charles J Prestigiacomo
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of PT951292E publication Critical patent/PT951292E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
PT97944453T 1996-09-27 1997-09-25 Métodos de tratamento de uma perturbação isquémica e de melhoria das consequências de acidente vascular cerebral. PT951292E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72144796A 1996-09-27 1996-09-27

Publications (1)

Publication Number Publication Date
PT951292E true PT951292E (pt) 2007-06-18

Family

ID=24898028

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97944453T PT951292E (pt) 1996-09-27 1997-09-25 Métodos de tratamento de uma perturbação isquémica e de melhoria das consequências de acidente vascular cerebral.

Country Status (10)

Country Link
EP (2) EP0951292B1 (https=)
JP (1) JP2001501612A (https=)
AT (1) ATE358492T1 (https=)
AU (1) AU4594297A (https=)
CA (1) CA2266640C (https=)
DE (1) DE69737562T2 (https=)
DK (1) DK0951292T3 (https=)
ES (1) ES2285740T3 (https=)
PT (1) PT951292E (https=)
WO (1) WO1998013058A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1712226A3 (en) * 1996-04-05 2007-03-21 The General Hospital Corporation Treatment of a Hemoglobinopathy
US6315995B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
WO1999049803A1 (en) * 1998-04-01 1999-10-07 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
FR2816212A1 (fr) * 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
US20030198639A1 (en) * 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP1404811B1 (en) * 2001-06-21 2008-11-12 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
US6472390B1 (en) * 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
US7011854B2 (en) 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
SG148850A1 (en) * 2002-02-13 2009-01-29 Beth Israel Hospital Methods of treating vascular disease
EA200401365A1 (ru) 2002-04-15 2005-04-28 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Способы лечения илеуса
WO2003088981A1 (en) * 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
WO2003088748A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
EA200401525A1 (ru) * 2002-05-17 2006-06-30 Йейл Юниверсити Способы лечения гепатита (варианты )
DE10230165A1 (de) 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Verfahren und Vorrichtung zur Administration von Kohlenmonoxid
EP1558084A4 (en) * 2002-11-07 2008-04-30 Univ Pittsburgh TREATMENT OF HEMORRHAGIC SHOCK
EP1684579A1 (en) 2003-10-22 2006-08-02 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
EP1552840A1 (en) * 2004-01-07 2005-07-13 Aga Ab Use of a xenon/carbon monoxide mixture for the protection of cells
SI2264043T1 (en) 2005-09-02 2018-01-31 Glycomimetics, Inc. HETEROBIFUNCTIONAL PAN-SELECTINE INHIBITORS
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
EP2356224A4 (en) * 2008-11-10 2012-12-26 Sinai School Medicine METHOD OF INHIBITING WEB TREATMENT IN CONNECTION WITH INFLAMMATION THROUGH NEUTROPHILACTIVITY INHIBITION
CN101732348B (zh) * 2008-11-11 2015-01-14 威世药业（如皋）有限公司 牛痘疫苗致炎兔皮提取物在制备急性脑血管疾病治疗药物中的用途
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
ES2628634T3 (es) 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
PT2794626T (pt) 2011-12-22 2018-01-12 Glycomimetics Inc Compostos de antagonistas de e-selectina
EP2842966B1 (en) 2012-04-27 2018-08-15 Nihon University Therapeutic agent for epithelial and endothelial injury
CA2891514C (en) 2012-12-07 2020-08-25 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
ES2754549T3 (es) 2014-12-03 2020-04-20 Glycomimetics Inc Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
EP3497131B1 (en) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
WO2019108750A1 (en) 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CN111566117A (zh) 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
WO2019173229A1 (en) 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
US20230263832A1 (en) * 2020-07-10 2023-08-24 Children's Medical Center Corporation Targeted drug delivery to sites of intravascular occlusion

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
ES2213141T3 (es) * 1992-05-22 2004-08-16 Montana State University Anticuerpos con especificidad hacia multiples moleculas de adhesion.
US5591835A (en) * 1992-06-29 1997-01-07 Glycomed Incorporated Substituted lactose derivatives
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
WO1994012215A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
WO1995020400A1 (en) * 1994-01-28 1995-08-03 Japan Tobacco Inc. Anti-inflammatory containing monoclonal antibodies having reactivity with sialyl-lewis x sugar chains originating in hemangioendothelial cell membrane
DE4403057C1 (de) * 1994-02-02 1994-12-08 Biotest Pharma Gmbh Thrombozytenstabilisierende Faktor IX-Fragmente, deren Herstellung sowie sie enthaltende Arzneimittel
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung

Also Published As

Publication number Publication date
EP1829550A2 (en) 2007-09-05
EP0951292A1 (en) 1999-10-27
DK0951292T3 (da) 2007-08-13
AU4594297A (en) 1998-04-17
DE69737562D1 (de) 2007-05-16
JP2001501612A (ja) 2001-02-06
WO1998013058A1 (en) 1998-04-02
EP0951292A4 (en) 2004-08-04
CA2266640C (en) 2011-05-24
CA2266640A1 (en) 1998-04-02
DE69737562T2 (de) 2007-12-27
EP1829550A3 (en) 2008-04-30
EP0951292B1 (en) 2007-04-04
ATE358492T1 (de) 2007-04-15
ES2285740T3 (es) 2007-11-16

Similar Documents

Publication Publication Date Title
PT951292E (pt) Métodos de tratamento de uma perturbação isquémica e de melhoria das consequências de acidente vascular cerebral.
US6316403B1 (en) Methods for treating an ischemic disorder and improving stroke outcome
US8128963B2 (en) Methods for treating ischemic disorders using carbon monoxide
WO1998013058A9 (en) Methods for treating an ischemic disorder and improving stroke outcome
US6315995B1 (en) Methods for treating an ischemic disorder and improving stroke outcome
Pinsky et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain
Høgåsen et al. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency.
Mannucci Treatment of von Willebrand's disease
Singbartl et al. Platelet, but not endothelial, P‐selectin is critical for neutrophil‐mediated acute postischemic renal failure
Kyriakides et al. Skeletal muscle reperfusion injury is mediated by neutrophils and the complement membrane attack complex
Bassuk et al. Liver fatty acid binding protein is the mitosis-associated polypeptide target of a carcinogen in rat hepatocytes.
US5679345A (en) Method for preventing complement-dependent rejection of organ or tissue transplants
PT95437B (pt) Processo de obtencao de sequencia de acido nucleico da proteina de cr1, de vectores contendo a referida sequencia, de celulas recombinantes, de preparacao e purificacao de proteinas de cr1 e de composicoes farmaceuticas
PT1007092E (pt) Um processo para inibir a activação do complemento pela via alternativa
UA124094C2 (uk) Спосіб лікування стану, пов'язаного з masp-2-залежною активацією комплементу
JP2011503012A (ja) 予後に関するバイオマーカーおよび治療の分子標的としての細胞外ヒストン
JPH08510257A (ja) 補体関連蛋白質および炭水化物よりなる組成物、ならびに該組成物の製法および使用方法
Wilcox et al. Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII
JP2006500008A (ja) 抗血小板自己抗体およびそのインヒビターに関連する組成物、方法およびキット
US20050250688A1 (en) Methods for treating an ischemic disorder and improving stroke outcome
US20060003930A1 (en) CD39/ecto-adpase for treatment of thrombotic and ischemic disorders
US20040136985A1 (en) Methods of modifying behavior of CD9-expressing cells
Moncada et al. The vascular endothelium II
MXPA99002996A (en) Methods for treating an ischemic disorder and improving stroke outcome
He et al. Thiol isomerase ERp18 enhances platelet activation and arterial thrombosis